📊 KRRO Key Takeaways
Is KRRO a Good Investment? Thesis Analysis
Korro Bio exhibits fundamental characteristics of a cash-burning pre-revenue biotech company with $121.9M operating losses against $6.4M revenue and unsustainable $78.6M annual operating cash burn. The company's $21.8M cash position provides only 3-4 months of runway at current burn rates, necessitating imminent dilutive capital raises. Without demonstrated clinical efficacy or profitability milestones visible in current fundamentals, the financial outlook is severely constrained.
Why Buy KRRO? Key Strengths
- Strong revenue growth of 181.5% YoY indicates early traction
- Excellent liquidity position with 6.90x current ratio and $21.8M cash
- Minimal debt burden with only $180K long-term debt, low leverage risk
KRRO Investment Risks to Consider
- Unsustainable cash burn of $78.6M annually against $21.8M cash (3-4 month runway)
- Catastrophic profitability metrics with operating margin of -1906% and net margin of -1834%
- Imminent need for dilutive capital raise to fund operations and potential clinical programs
Key Metrics to Watch
- Monthly operating cash burn rate and cash runway
- Clinical trial progression and regulatory milestones
- Capital raise announcements and dilution impact on equity
KRRO Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.90x current ratio provides a solid financial cushion.
KRRO Profitability Ratios
KRRO vs Healthcare Sector
How Korro Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KRRO Overvalued or Undervalued?
Based on fundamental analysis, Korro Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KRRO Balance Sheet & Liquidity
KRRO 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Korro Bio, Inc.'s revenue has declined by 51% over the 5-year period, indicating business contraction. The most recent EPS of $-9.37 indicates the company is currently unprofitable.
KRRO Growth Metrics (YoY)
KRRO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$18.1M | $-1.92 |
| Q2 2025 | N/A | -$19.6M | $-2.43 |
| Q1 2025 | N/A | -$19.6M | $-2.44 |
| Q3 2022 | N/A | -$19.5M | N/A |
| Q2 2022 | N/A | -$17.7M | N/A |
| Q1 2022 | N/A | -$20.4M | N/A |
| Q3 2021 | $11.2M | -$5.3M | N/A |
| Q2 2021 | $8.5M | -$6.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KRRO Capital Allocation
KRRO SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Korro Bio, Inc. (CIK: 0001703647)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KRRO
What is the AI rating for KRRO?
Korro Bio, Inc. (KRRO) has an AI rating of STRONG SELL with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KRRO's key strengths?
Claude: Strong revenue growth of 181.5% YoY indicates early traction. Excellent liquidity position with 6.90x current ratio and $21.8M cash.
What are the risks of investing in KRRO?
Claude: Unsustainable cash burn of $78.6M annually against $21.8M cash (3-4 month runway). Catastrophic profitability metrics with operating margin of -1906% and net margin of -1834%.
What is KRRO's revenue and growth?
Korro Bio, Inc. reported revenue of $6.4M.
Does KRRO pay dividends?
Korro Bio, Inc. does not currently pay dividends.
Where can I find KRRO SEC filings?
Official SEC filings for Korro Bio, Inc. (CIK: 0001703647) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KRRO's EPS?
Korro Bio, Inc. has a diluted EPS of $-12.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KRRO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Korro Bio, Inc. has a STRONG SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KRRO stock overvalued or undervalued?
Valuation metrics for KRRO: ROE of -228.0% (sector avg: 15%), net margin of -1,834.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KRRO stock in 2026?
Our dual AI analysis gives Korro Bio, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KRRO's free cash flow?
Korro Bio, Inc.'s operating cash flow is $-78.6M, with capital expenditures of $518.0K. FCF margin is -1,237.2%.
How does KRRO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,834.5% (avg: 12%), ROE -228.0% (avg: 15%), current ratio 6.90 (avg: 2).